EXCLUSIVE: Medical Cannabis Is Growing And Profitable, Says Aurora CEO — Investors Are Just Missing The Story
Shares of Aurora Cannabis Inc (NASDAQ:ACB) fell roughly 20% on Wednesday following the company’s fiscal Q4 and full-year 2025 earnings report, even after reporting record-high medical cannabis revenue, adjusted EBITDA and positive free cash flow.
But CEO Miguel Martin isn’t sweating the reaction.
“It was record earnings, record EBITDA, record free cash flow for the year,” Martin told Benzinga. “Given the totality of the year and the quarter we put forth, I think it’s a bit of an overreaction, but I understand it. I know people are sensitive.”
A Temporary Dip, Not a Trend
The company forecasted a short-term dip in international cannabis sales for the current quarter. Some investors seized on that detail, sending the stock lower.
“All [the guidance] said was that Q1 was going to be a little bit less in revenue and EBITDA connected to international cannabis than Q4,” Martin explained. “We expect it to come back in Q2. We expect to be free cash flow positive for Q1 and for the year.”
That Q1 softness, he added, is tied to short-term challenges in two of Aurora’s core international markets.
“In Poland, it’s about the regulatory process for patients to get prescriptions. In the UK, we had a little bit of timing as we brought …